In patients with type 2 diabetes, SGLT2 inhibitors provide benefits such as reducing the risk of hyperglycemia, facilitating weight loss, and lowering blood pressure [74]. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.